G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics to Participate Virtually in the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 08:00:29 By Nasdaq GlobeNewswire

G1 Therapeutics to Host Virtual R&D Day on September 15, 2022

06 Sep 2022 07:00:15 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2022 17:22:08 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights

03 Aug 2022 06:30:32 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2022 17:15:05 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

25 Jul 2022 06:30:43 By Nasdaq GlobeNewswire

G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022

20 Jul 2022 09:00:31 By Nasdaq GlobeNewswire

COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

13 Jul 2022 10:15:28 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2022 17:20:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors

28 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

13 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy

02 Jun 2022 11:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jun 2022 16:45:00 By Nasdaq GlobeNewswire

G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal

20 May 2022 10:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference

18 May 2022 10:15:00 By Nasdaq GlobeNewswire

G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights

04 May 2022 06:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2022 17:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022

21 Apr 2022 08:30:01 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

06 Apr 2022 11:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Apr 2022 16:15:23 By Nasdaq GlobeNewswire